Moderna announced a major strategic pivot, ceasing investment in new late-stage vaccine trials and instead redirecting capital toward its oncology and heart disease pipelines.
- The decision to halt new vaccine investment was cited due to increasing regulatory scrutiny of immunizations from U.S. officials.
- This strategic shift follows a massive multi-day stock rally driven by strong five-year data for its personalized cancer therapy collaboration with Merck, which included a 4.14% gain on January 22.